Effect of Adjuvant Therapy by Sorafenib, Oxaliplatin and S-1
NCT ID: NCT02129322
Last Updated: 2021-02-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE2
INTERVENTIONAL
2015-07-31
2019-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Impact of Postoperative Adjuvant Chemotherapy in Patients With Hepatocellular Carcinoma After Liver Transplantation
NCT01125020
Systemic Chemotherapy Plus Lenvatinib and Toripalimab for HCC With Extrahepatic Metastasis
NCT04170179
Relenvatinib in the Tatment of Recurrence of Hepatocellular Carcinoma After Liver Transplantation
NCT04237740
Efficacy and Safety of Sorafenib as Adjuvant and Latter Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma
NCT03097848
HAIC of FOLFOX vs. HAIC of OXA for Advanced HCC
NCT03468231
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sorafenib
Leading 4 cycles: S-1 + Oxaliplatin Q3W + Sorafenib daily Sequential : Sorafenib maintenance
Sorafenib
S-1
Oxaliplatin
S-1 and Sorafenib
Leading 4 cycles: S-1 + Oxaliplatin Q3W + Sorafenib daily Sequential : 4 cycles of S-1 + Sorafenib maintenance
Sorafenib
S-1
Oxaliplatin
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sorafenib
S-1
Oxaliplatin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Major organ (heart, lung and brain) function was normal
Exclusion Criteria
* The presence of clinically confirmed extrahepatic metastasis
* Postoperative dysfunction of any organ
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Zhejiang University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Weijia Fang, MD
First affiliated hospital, Zhejiang University
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Weijia fang
Role: PRINCIPAL_INVESTIGATOR
First Affiliated Hospital,Zhejiang University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
First affiliated hospital, Zhejiang University
Hangzhou, , China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ZYYYMedOncoLT01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.